Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05264051

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,200 (estimated)
Sponsor
University of Chicago · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Detailed description

Prospective study of patients seen at the Univ. of Chicago Medical Center hospital and ambulatory clinics. The assessment of the MAsS score will require an additional 8-10 minutes in the MRI for each patient already undergoing MRI exam. Four groups of pts. who are already scheduled for MRI for routine clinical purposes will be evaluated. 1. Pts. hospitalized with acute hepatic decompensation for whom MRI is otherwise indicated for clinical evaluation. 2. Pts. with hepatobiliary neoplasia 3. Pts.undergoing transjugular portosystemic shunt (TIPS) placement 4. Pts. with chronic liver disease undergoing magnetic resonance elastography for routine monitoring

Conditions

Timeline

Start date
2022-04-18
Primary completion
2027-03-01
Completion
2027-03-01
First posted
2022-03-03
Last updated
2026-01-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05264051. Inclusion in this directory is not an endorsement.